Breaking News from Maui Derm 2024: Nemolizumab Improves Lesions, Relieves Itch in AD
Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis. The research was presented by Jonathan I Silverberg, MD, Associate Professor of Dermatology and Director of Clinical […]